Rare Pediatric Invasive Gliofibroma Has BRAFV600E Mutation and Transiently Responds to Targeted Therapy Before Progressive Clonal Evolution.
作者信息
Kaneva Kristiyana, Yeo Kee Kiat, Hawes Debra, Ji Jianling, Biegel Jaclyn A, Nelson Marvin D, Bluml Stefan, Krieger Mark D, Erdreich-Epstein Anat
机构信息
Division of Hematology, Oncology, and Blood and Marrow Transplant Program, Children's Center for Cancer and Blood Diseases, Department of Pediatrics, Children's Hospital Los Angeles.
Department of Pathology, University of Southern California, Los Angeles, CA.
出版信息
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00138. Epub 2019 Mar 27.
Abstract
摘要
相似文献
1
Rare Pediatric Invasive Gliofibroma Has BRAFV600E Mutation and Transiently Responds to Targeted Therapy Before Progressive Clonal Evolution.罕见小儿侵袭性胶质纤维瘤具有BRAFV600E突变，并在进行性克隆进化前对靶向治疗产生短暂反应。
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00138. Epub 2019 Mar 27.
2
Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.转移相关的MCL1和P16拷贝数改变决定了BRAFV600E患者来源的甲状腺乳头状癌临床前模型对维莫非尼的耐药性。
Oncotarget. 2015 Dec 15;6(40):42445-67. doi: 10.18632/oncotarget.6442.
3
BRAF mutation: A promising target in colorectal neuroendocrine carcinoma.BRAF 突变：结直肠神经内分泌癌有前途的靶点。
Int J Cancer. 2019 Mar 15;144(6):1379-1390. doi: 10.1002/ijc.31828. Epub 2018 Oct 30.
4
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.达拉非尼联合或不联合维莫非尼治疗BRAF突变的非小细胞肺癌。
PLoS One. 2015 Feb 23;10(2):e0118210. doi: 10.1371/journal.pone.0118210. eCollection 2015.
5
V600E Inhibitor (Vemurafenib) for V600E Mutated Low Grade Gliomas.用于V600E突变型低级别胶质瘤的V600E抑制剂（维莫非尼）
Front Oncol. 2018 Nov 14;8:526. doi: 10.3389/fonc.2018.00526. eCollection 2018.
6
Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.应用液滴式数字 PCR 对接受 BRAF 抑制剂治疗的黑色素瘤患者进行定量的无细胞循环 BRAFV600E 突变分析。
Clin Chem. 2015 Jan;61(1):297-304. doi: 10.1373/clinchem.2014.230235. Epub 2014 Nov 19.
7
EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.表皮生长因子受体（EGFR）阻断可防止胶质瘤逃避BRAFV600E靶向治疗。
Oncotarget. 2015 Sep 8;6(26):21993-2005. doi: 10.18632/oncotarget.4014.
8
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.在一种新型同基因小鼠胶质瘤模型中，同时进行的MEK靶向治疗可防止BRAFV600E靶向抑制期间MAPK通路的重新激活。
Oncotarget. 2016 Nov 15;7(46):75839-75853. doi: 10.18632/oncotarget.12419.
9
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.维莫非尼联合伊立替康和西妥昔单抗治疗BRAFV600E突变转移性结直肠癌患者的I B期研究
Cancer Discov. 2016 Dec;6(12):1352-1365. doi: 10.1158/2159-8290.CD-16-0050. Epub 2016 Oct 11.
10
Panniculitis Under Successful Targeted Inhibition of the MAPK/ERK Signaling Pathway in a Patient With BRAF V600E-mutated Spindle Cell Oncocytoma of the Pituitary Gland.在一名患有BRAF V600E突变的垂体腺梭形细胞嗜酸细胞瘤患者中，丝裂原活化蛋白激酶/细胞外信号调节激酶（MAPK/ERK）信号通路成功靶向抑制后出现的脂膜炎
Anticancer Res. 2019 Jul;39(7):3955-3959. doi: 10.21873/anticanres.13549.
引用本文的文献
1
Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults.综合基因组分析在儿童和青年中枢神经系统肿瘤中的临床应用
Neurooncol Adv. 2021 Feb 25;3(1):vdab037. doi: 10.1093/noajnl/vdab037. eCollection 2021 Jan-Dec.
2
Detection of mitochondrial DNA variants at low level heteroplasmy in pediatric CNS and extra-CNS solid tumors with three different enrichment methods.采用三种不同富集方法检测儿科 CNS 和中枢神经系统外实体瘤中低水平异质性的线粒体 DNA 变异体。
Mitochondrion. 2020 Mar;51:97-103. doi: 10.1016/j.mito.2020.01.006. Epub 2020 Jan 20.
本文引用的文献
1
OncoKids: A Comprehensive Next-Generation Sequencing Panel for Pediatric Malignancies.儿童肿瘤基因检测 panel：用于儿科恶性肿瘤的新一代测序综合 panel
J Mol Diagn. 2018 Nov;20(6):765-776. doi: 10.1016/j.jmoldx.2018.06.009. Epub 2018 Aug 20.
2
Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?靶向 SHP-1、2 和 SHIP 通路：癌症治疗的新策略？
Oncology. 2018;95(5):257-269. doi: 10.1159/000490106. Epub 2018 Jun 20.
3
Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With -Mutated High-Grade Glioma.达拉非尼联合曲美替尼治疗携带 BRAF V600E 突变的高级别胶质瘤成人患者的快速临床和影像学反应。
J Natl Compr Canc Netw. 2018 Jan;16(1):4-10. doi: 10.6004/jnccn.2017.7032.
4
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.对 282 例儿童低级别和高级别神经胶质瘤的全面基因组分析揭示了基因组驱动因素、肿瘤突变负担和超突变特征。
Oncologist. 2017 Dec;22(12):1478-1490. doi: 10.1634/theoncologist.2017-0242. Epub 2017 Sep 14.
5
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.BRAF V600E在儿童低级别胶质瘤中的治疗及预后意义
J Clin Oncol. 2017 Sep 1;35(25):2934-2941. doi: 10.1200/JCO.2016.71.8726. Epub 2017 Jul 20.
6
Midbrain Gliofibroma Presenting in Adulthood following "Cure" of a Childhood Intraventricular Pilocytic Astrocytoma.儿童期脑室内毛细胞型星形细胞瘤“治愈”后成年期出现的中脑胶质纤维瘤
Pediatr Neurosurg. 2017;52(3):151-154. doi: 10.1159/000455920. Epub 2017 Mar 1.
7
COSMIC: somatic cancer genetics at high-resolution.COSMIC：高分辨率体细胞癌遗传学
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783. doi: 10.1093/nar/gkw1121. Epub 2016 Nov 28.
8
Combined BRAF and MEK blockade for BRAF-mutant gliomas.联合BRAF和MEK阻断治疗BRAF突变型胶质瘤。
J Neurooncol. 2017 Feb;131(3):495-505. doi: 10.1007/s11060-016-2333-4. Epub 2016 Nov 15.
9
Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.儿童高级别胶质瘤中血小板衍生生长因子受体A（PDGFRA）改变的特征及靶向治疗
Oncotarget. 2016 Oct 4;7(40):65696-65706. doi: 10.18632/oncotarget.11602.
10
Structural and biochemical studies of the PDGFRA kinase domain.血小板衍生生长因子受体A激酶结构域的结构与生化研究。
Biochem Biophys Res Commun. 2016 Sep 2;477(4):667-672. doi: 10.1016/j.bbrc.2016.06.117. Epub 2016 Jun 24.
Zotero 插件